BRAF and non-small cell lung carcinoma: For instance, mutations in the epidermal growth factor receptor (EGFR) have been linked to resistance against tyrosine kinase inhibitors in non-small-cell lung cancer (NSCLC), whereas BRAF mutations have been shown to drive resistance in melanoma treatment [6].